MDT Medtronic
Intrinsic value$19.78
Price (at call)$92.60
Margin of safety
-78.6%
vs market (rating basis)
-45.1%
Model unavailable; showing baseline valuation.
⚠ LLM error: empty response; using baseline
The story
Value drivers
| Revenue growth (Y1) | 5.2% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | 14.8% |
| Years to target margin | 5 |
| Sales-to-capital | 0.50 |
| Beta | 0.57 |
| Failure probability | 0.0% |
| Cost of capital (WACC) | 7.3% |
| Terminal WACC | 8.9% |
Valuation bridge
| PV of explicit FCFF | 13.24B |
| PV of terminal value | 38.62B |
| Equity value | 25.30B |
| ÷ shares → per share | $19.78 |
News
bullish +0.30 · 8 articles
- Should You Judge JNJ Stock Without STELARA?
- Recor Medical ex-CEO Lara Barghout joins Medtronic
- How Medtronic’s (MDT) AI Maternal Health Push With Sonus Is Reframing Its Investment Story
- Medtronic Sees AI, Ablation and Targeted M&A Fueling Growth
- Has BSX Stock Finally Hit Bottom?
- Boston Scientific Leans on Acquisitions to Drive Long-Term Growth
- Get Paid To Wait For ISRG Stock To Go On Sale
- Medtronic begins final steps to separate MiniMed
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 39.50B | 5.2% | 18.6% | 5.78B | 3.91B | 1.87B | 1.74B |
| 2 | 41.48B | 5.0% | 17.6% | 5.76B | 3.96B | 1.80B | 1.56B |
| 3 | 43.48B | 4.8% | 16.7% | 5.71B | 4.01B | 1.71B | 1.38B |
| 4 | 45.50B | 4.6% | 15.7% | 5.64B | 4.03B | 1.60B | 1.21B |
| 5 | 47.52B | 4.4% | 14.8% | 5.53B | 4.05B | 1.48B | 1.04B |
| 6 | 49.55B | 4.3% | 14.8% | 5.76B | 4.05B | 1.72B | 1.12B |
| 7 | 51.56B | 4.1% | 14.8% | 6.00B | 4.03B | 1.97B | 1.20B |
| 8 | 53.56B | 3.9% | 14.8% | 6.23B | 4.00B | 2.23B | 1.27B |
| 9 | 55.54B | 3.7% | 14.8% | 6.46B | 3.95B | 2.51B | 1.33B |
| 10 | 57.48B | 3.5% | 14.8% | 6.69B | 3.89B | 2.80B | 1.38B |